Balofloxacinの性器組織内移行と産婦人科領域感染症に対する臨床効果  [in Japanese] The transfer of balofloxacin to genital tissues and itsclinical effects on obstetric and gynecological infectious diseases  [in Japanese]

Access this Article

Search this Article



新規経口用キノロン薬balofloxacin 100mgまたは200mgを単回経口投与すると最高血中濃度はそれぞれ1.1~1.2μg/ml, 1.6~1.8μg/mlに達した。これに比し, 女性性器組織内の最高濃度は1.4~2.5μg/gおよび2.0~4.2μg/gに達し, 血中より高くなることが認められた。<BR>一方, 卵管炎7例およびバルトリン腺膿瘍1例を対象に本剤400mg (分2) を5~7日間反復経口投与したところ, 全ての症例で有効と判定される感染症状の改善が認められた。起炎菌は2例より分離され, いずれも消失した。<BR>副作用は全く発現しなかった。臨床検査では好酸球の軽度増多が1例で発現したのみであった。

When a new fluoroquinolone, balofloxacin, was orally administered the maximum concentration in blood reached 1.1-1.2μg/ml for the 100 mg dose and 1.6-1.8μg/ml for the 200 mg dose. The maximum concentration in female genital organ tissues was 1.4-2.5μg/g for 100 mg and 2.0-4.2μg/g for 200 mg, both higher than the blood concentrations.<BR>When the drug was repeatedly administered to seven patients with salpingitis and one with Bartholin's abscess, at a dose of 400 mg (in 2 divisions) for 5-7 days, the infectious symptoms improved suggesting that BLFX was effective in all 8 patients. Pyogenic bacteria were isolated from two patients were eradicated.<BR>No side effects occurred. Slight eosinophilia was observed, only in one patient.


  • Japanese Journal of Chemotherapy

    Japanese Journal of Chemotherapy 43, 434-438, 1995-11-27

    Japanese Society of Chemotherapy

References:  8


Page Top